Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
groupe-lfb.com

See what CB Insights has to offer

Investments

2

Partners & Customers

8

About LFB Biomedicaments

LFB Biomedicaments is a manufacturer of pharmaceutical products. The company researches and develops plasma-derived medications to treat therapeutic areas of immunology, intensive care, hemostasis, and rare diseases.

LFB Biomedicaments Headquarters Location

3 Avenue des Tropiques

Courtaboeuf, 40 305,

France

+33 0169827004

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

LFB Biomedicaments Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

LFB Biomedicaments Rank

Latest LFB Biomedicaments News

Global Kawasaki Disease Treatment Market 2021:Size,Share,Competitive Analysis,Insights,Forecast To 2028||LFB Biomedicaments S.A., Kedrion S.p.A., Octapharma AG, Sanquin Plasma Products B.V

Apr 9, 2021

||LFB Biomedicaments S.A., Kedrion S.p.A., Octapharma AG, Sanquin Plasma Products B.V Advanced report on Global Kawasaki Disease Treatment Market Added by Data Bridge Market Research, offers details on current and future growth trends pertaining to the business besides information on myriad regions across the geographical landscape of the Kawasaki Disease Treatment Market. The report also expands on comprehensive details regarding the supply and demand analysis, participation by major industry players and market share growth statistics of the business sphere. This comprehensive Kawasaki disease treatment industry research report includes a brief on these trends that can help the organizations operating in the industry to understand the market and strategize for their business expansion accordingly. The research report analyzes the market CAGR,Volume, industry share And size, demand and trend growth, key segments, and key drivers and restrains. New Players in the market are facing tough competition from established international  Players as they struggle with technological innovations, reliability and quality issues. The report will answer questions about the current market developments and the scope of competition, opportunity cost and more. Download Exclusive Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this Industry @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-kawasaki-disease-treatment-market Kawasaki disease treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 6.80% in the above-mentioned research forecast period. The Major Players Covered In The Kawasaki Disease Treatment Market Are Takeda Pharmaceutical Company Limited, CSL, Grifols, S.A., ( Gamma  Globulin, Monoclonal Antibodies, Steroids, NSAIDs), Kawasaki Disease Treatment Market By Route of Administration (Oral, Parenteral, Others), (Clinics, Hospitals, Homecare, Others), (Hospital Pharmacy, Retail Pharmacy,  Online  Pharmacy, Others), Kawasaki Disease Treatment Market By Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) For More Information Or Query Or Customization Before Buying Visit@ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-kawasaki-disease-treatment-market Global Kawasaki Disease Treatment Market Drivers: Rapid rise in incidence of kawasaki disease in the emerging countries and increase in adoption of intravenous  immunoglobulin  therapy in order to prevent or reduce the coronary artery problem are some factors driving the market growth. Moreover, increasing focus of market players towards the development of advanced treatment options and the underlining clinical trials using different drugs such as steroids and infliximab to treat the disease as the second line and tertiary treatment also boost up the market growth. Moreover, increasing research and development and rising healthcare expenditure act as opportunities for the market growth. Global Kawasaki Disease Treatment Market Restraints: Sometimes adverse effect related to the drugs, strict regulatory framework and high cost of biological therapy among others may hamper the global Kawasaki disease treatment market. Access Full Report @ https://www.databridgemarketresearch.com/reports/global-kawasaki-disease-treatment-market Insights of the Study Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the trocars market Market Penetration: Comprehensive information on the product portfolios of the top players in the Kawasaki disease treatment market To strategically profile key players and comprehensively analyze their market position in terms of ranking and core competencies, and detail the competitive landscape for market leaders The key findings and recommendations highlight crucial progressive industry trends in the Kawasaki disease treatment Market, thereby allowing players to develop effective long term strategies Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to products, segmentation and industry verticals. Kawasaki Disease Treatment Market Country Level Analysis Kawasaki disease treatment market is analysed and market size information is provided by country, treatment, route of administration, end-users and distribution channel as referenced above. The countries covered in the Kawasaki disease treatment market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa. On geographical estimation, North America accounts the largest market share due to the rising cases of Kawasaki disease in the U.S with reported 4,200 children in the U.S every year. Moreover, rising governmental concern towards the children health and increasing research and development activities is also boosting the growth of market. Asia-Pacific is expected to account for the largest market share owing to increase in incidence of acquired congenital heart disease caused due to Kawasaki disease. Moreover, increasing prevalence of KD in Japan with reported 1 affected child in every 100 children is another factor boosting the Asia Pacific market. Table Of Content: Executive Summary Global Kawasaki disease treatment Market: Growth and Forecast Global Kawasaki disease treatment Market: Company Share Global Kawasaki disease treatment Market: Regional Analysis North America Kawasaki disease treatment Market: An Analysis Europe Kawasaki disease treatment Market: An Analysis APAC Kawasaki disease treatment Market: An Analysis ROW Kawasaki disease treatment Market: An Analysis Global Kawasaki disease treatment Market: Market Dynamics Porter Five Force Analysis Company Profiles Points Covered in The Report: The points that are discussed within the report are the major market players that are involved in the Kawasaki disease treatment market. The complete profile of the companies is mentioned. The production, sales, future strategies, and the technological developments that they are making are also included within the report. The growth factors of the Kawasaki disease treatment market is discussed in detail wherein the different end users of the market are explained in detail. The application areas of the Kawasaki disease treatment market are also discussed thus giving a broad idea about the market to the clients. The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included. Reasons to buy this report: To get a comprehensive overview of the Kawasaki disease treatment To gain information about the top players in this industry, their product portfolios, and their key strategies. To gain insights about the major regional insights in which the Kawasaki disease treatment is flourishing. Recent industry trends and developments Potential and niche segments/regions exhibiting promising growth About Us: Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing  sopan.gedam@databridgemarketresearch.com  . We are content with our glorious 99.9 % client satisfying rate. Contact:

LFB Biomedicaments Investments

2 Investments

LFB Biomedicaments has made 2 investments. Their latest investment was in GamaMabs Pharma as part of their Seed VC on September 9, 2013.

CBI Logo

LFB Biomedicaments Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/30/2013

Seed VC

GamaMabs Pharma

$4.2M

Yes

1

9/30/2013

Series A

Subscribe to see more

Subscribe to see more

0

Date

9/30/2013

9/30/2013

Round

Seed VC

Series A

Company

GamaMabs Pharma

Subscribe to see more

Amount

$4.2M

New?

Yes

Subscribe to see more

Co-Investors

Sources

1

0

LFB Biomedicaments Acquisitions

1 Acquisition

LFB Biomedicaments acquired 1 company. Their latest acquisition was CAF-DCF on July 08, 2016.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

7/8/2016

$99M

Acquired

1

Date

7/8/2016

Investment Stage

Companies

Valuation

$99M

Total Funding

Note

Acquired

Sources

1

LFB Biomedicaments Partners & Customers

8 Partners and customers

LFB Biomedicaments has 8 strategic partners and customers. LFB Biomedicaments recently partnered with Xenothera on April 4, 2020.

Date

Type

Business Partner

Country

News Snippet

Sources

4/15/2020

Partner

France

LFB SIGNS AGREEMENT WITH XENOTHERA TO MANUFACTURE FIRST CLINICAL BATCH OF XENOTHERA'S XAV-19 FOR THE TREATMENT OF CORONAVIRUS INFECTIONS INCLUDING COVID-19 - LFB corp Home › News › LFB SIGNS AGREEMENT WITH XENOTHERA TO MANUFACTURE FIRST CLINICAL BATCH OF XENOTHERA’S XAV-19 FOR THE TREATMENT OF CORONAVIRUS INFECTIONS INCLUDING COVID-19.

Odile Duvaux , President of XENOTHERA added : `` We are very pleased with this collaboration with LFB , a French pharmaceutical company well-versed in antibody technologies , that responded favourably to our request for urgent action in these times when the health emergency is the top priority .

1

2/20/2017

Partner

Canada

Subscribe to see more

Subscribe to see more

10

6/30/2016

Licensee

China

Subscribe to see more

Subscribe to see more

10

3/18/2016

Vendor

United States

Subscribe to see more

Subscribe to see more

10

2/20/2013

Partner

Canada

Subscribe to see more

Subscribe to see more

10

Date

4/15/2020

2/20/2017

6/30/2016

3/18/2016

2/20/2013

Type

Partner

Partner

Licensee

Vendor

Partner

Business Partner

Country

France

Canada

China

United States

Canada

News Snippet

LFB SIGNS AGREEMENT WITH XENOTHERA TO MANUFACTURE FIRST CLINICAL BATCH OF XENOTHERA'S XAV-19 FOR THE TREATMENT OF CORONAVIRUS INFECTIONS INCLUDING COVID-19 - LFB corp Home › News › LFB SIGNS AGREEMENT WITH XENOTHERA TO MANUFACTURE FIRST CLINICAL BATCH OF XENOTHERA’S XAV-19 FOR THE TREATMENT OF CORONAVIRUS INFECTIONS INCLUDING COVID-19.

Odile Duvaux , President of XENOTHERA added : `` We are very pleased with this collaboration with LFB , a French pharmaceutical company well-versed in antibody technologies , that responded favourably to our request for urgent action in these times when the health emergency is the top priority .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

LFB Biomedicaments Team

7 Team Members

LFB Biomedicaments has 7 team members, including current Chief Executive Officer, Denis DELVAL.

Name

Work History

Title

Status

Denis DELVAL

Chief Executive Officer

Current

Olivier Grellier

Chief Financial Officer

Current

David LOISON

Chief Financial Officer

Current

Hélène Guéry

Chief Marketing Officer

Current

Benjamin MERY

Chief Executive Officer, Chief Financial Officer, Senior Vice President

Former

Name

Denis DELVAL

Olivier Grellier

David LOISON

Hélène Guéry

Benjamin MERY

Work History

Title

Chief Executive Officer

Chief Financial Officer

Chief Financial Officer

Chief Marketing Officer

Chief Executive Officer, Chief Financial Officer, Senior Vice President

Status

Current

Current

Current

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.